Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Transition Therapeutics and Lilly's newest deal focuses on osteoarthritis

Executive Summary

Transition Therapeutics Inc. (treatments for CNS, metabolic, and musculoskeletal conditions) has once again expanded its relationship with partner Eli Lilly & Co., this time getting exclusive rights to the Big Pharma’s preclinical osteoarthritis candidate TT601.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register